Interplay Between Psychological Burden, Economic Stress, and Quality of Life in Chronic Myeloid Leukemia Care: An Integrated Analysis
- 10 March 2026
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2500967
Abstract
PURPOSE: As survival rates among patients with chronic myeloid leukemia (CML) have improved significantly, treatment goals have expanded from disease control to optimizing long-term quality of life (QoL). METHODS: The multicenter cross-sectional study used relevant survey questionnaires to gather comprehensive data on baseline characteristics, clinical treatment, economic burdens, psychological status, adverse events (AEs), and QoL among patients with CML. RESULTS: In all, 2,035 valid questionnaires were included for analysis. Psychological burden assessments indicate a high prevalence of mental health symptoms: 38.5% of patients report experiencing anxiety symptoms, whereas 46% exhibit symptoms of depression. This study identified a high-burden group experiencing significant economic and psychological stressors, which are associated with poor clinical responses. Psychological burden is central to the psychosocial clinical network and exhibits the strongest correlation with QoL ( r = 0.64). Notably, the mediation model indicates that psychological burden fully mediates the effect of economic burden on QoL (85.3%) and partially mediates its influence on medication adherence (35.5%). Furthermore, we identified a clinically significant subgroup characterized as QoL lag—patients who achieve deep molecular response but report low QoL. This discrepancy is independently predicted by multiple AEs (≥6 types: OR = 2.09), serious AEs (OR = 1.90), comorbidities (OR = 2.44), and escalating psychological burden (OR = 1.59). CONCLUSION: The findings underscore the need to shift the treatment of CML toward a holistic management paradigm. Clinical practice must actively engage with patients' concerns to optimize treatment efficacy, adjust drug dosages appropriately, and integrate social resources to provide psychological, economic, and familial support.Keywords
This publication has 25 references indexed in Scilit:
- Chronic Myeloid LeukemiaJAMA, 2025
- Prevalence and correlates of generalized anxiety disorder and subthreshold anxiety symptoms in south China: A network perspectiveJournal of Affective Disorders, 2025
- Adherence to tyrosine kinase inhibitor and clinical outcomes in patients with chronic myeloid leukemiaInternational Immunopharmacology, 2023
- Measuring chronic myeloid leukaemia TKI-related toxic effects in the real world: a systematic review and critical assessment of content validity of patient-reported outcome measuresThe Lancet Haematology, 2023
- Analysis of the prevalence and influencing factors of anxiety and depression in the Chinese population: A cross-sectional surveyHeliyon, 2023
- A Systematic Literature Review of the Economic Evaluations of Treatments for Patients with Chronic Myeloid LeukemiaPharmacoEconomics, 2022
- The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USAThe Lancet Haematology, 2022
- Chronic myeloid leukaemiaThe Lancet, 2021
- Sensitivity to change and minimal clinically important difference of the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7)Journal of Affective Disorders, 2020
- Estimating an EQ-5D-5L Value Set for ChinaValue in Health, 2017